RENBIO
LIVE

Serial Number

90309237

Owner

RENBIO, INC.

Attorney

Rachelle A. Dubow, Esq.

First Use Date

Nov 7, 2024

Filing Date

Nov 10, 2020

Add to watchlist:

No watchlists yet
View on USPTO

RENBIO Trademark

Serial Number: 90309237

RENBIO is a trademark filed by RENBIO, INC. on November 10, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently pending registration.

Owner Contact Info

RENBIO, INC. (4 trademarks)

30-02 48TH AVENUE
LONG ISLAND CITY, NY 11101

Entity Type: 03

Trademark Details

Filing Date

November 10, 2020

Registration Date

Not Registered

First Use Anywhere

November 7, 2024

First Use in Commerce

November 7, 2024

Published for Opposition

November 9, 2021

Goods & Services

Chemical preparations for gene delivery pharmaceuticals for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for therapeutic analysis; biochemical preparations for medical and veterinary purposes, namely, biochemical preparations for gene therapy, for treating genetic disorders, and for use as medical and veterinary diagnostic reagents for gene therapy analysis; Gene therapy and prophylactic products, namely, gene delivery pharmaceuticals for the treatment of genetic or cell based conditions; Pharmaceutical preparations containing nucleic acid sequences that encode monoclonal antibodies for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical compositions for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Biological preparations for the treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Nucleic acid sequences for medical purposes; Pharmaceutical compositions, namely, a nucleotide sequence that encodes an antigen, such as a DNA plasmid having an antigen encoding sequence and like DNA, for the prevention and treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; Pharmaceutical preparations for human use for the treatment and prevention of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders; pharmaceutical preparations for human and veterinary use, namely, antibiotics, antifungals and anti-virals

Biological products, namely, DNA circle, DNA primers, linear DNA and buffers for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals; Biological products, namely, antibodies, multi-specific antibodies, antibody fragments, proteins, chimeric proteins, drug conjugates and enzymes, for use in research and development of pharmaceuticals and for manufacture of pharmaceuticals

Medical apparatus for the administration of biopharmaceuticals and vaccines, namely, drug delivery devices and systems being pulse and waveform generators for the delivery of sub-dermal or intramuscular or intravenous drugs; medical devices, namely, pulse and waveform generators for electroporation mediated administration of drugs to humans and animals; delivery systems comprised of pulse and waveform generators for the delivery of sub-dermal or intramuscular or intravenous drugs for administration of biopharmaceuticals and vaccines for the preventive or treatment of disease in humans and animals; handheld medical systems and devices comprised of pulse and waveform generators using electroporation for the prevention or treatment of cancer, autoimmune diseases, rare diseases, infectious diseases, inflammatory diseases, and blood disorders in humans and animals; handheld clinical delivery systems and devices comprised of pulse and waveform generators for the application of electrical fields in tissue, in particular muscle and skin, in conjunction with the administration of biopharmaceuticals

Filing History

STATEMENT OF USE PROCESSING COMPLETE
Jan 3, 2025 SUPC
USE AMENDMENT FILED
Dec 18, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Dec 18, 2024 EISU
CORRECTED NOA E-MAILED
Sep 13, 2024 NOAC
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 2, 2024 EXRA
SOU EXTENSION 5 GRANTED
Jul 2, 2024 EX5G
SOU EXTENSION 5 FILED
Jul 2, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Jul 2, 2024 EEXT
DIVISIONAL PROCESSING COMPLETE
Jun 28, 2024 DPCC
DIVISIONAL REQUEST RECEIVED
Jun 28, 2024 DRRR
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jun 27, 2024 AITU
TEAS REQUEST TO DIVIDE RECEIVED
Jun 20, 2024 ERTD
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 12, 2023 EXRA
SOU EXTENSION 4 GRANTED
Dec 8, 2023 EX4G
SOU EXTENSION 4 FILED
Dec 8, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Dec 8, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 22, 2023 EXRA
SOU EXTENSION 3 GRANTED
Jun 20, 2023 EX3G
SOU EXTENSION 3 FILED
Jun 20, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 20, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 5, 2023 EXRA
SOU EXTENSION 2 GRANTED
Jan 3, 2023 EX2G
SOU EXTENSION 2 FILED
Jan 3, 2023 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 3, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jul 5, 2022 EXRA
SOU EXTENSION 1 GRANTED
Jul 1, 2022 EX1G
SOU EXTENSION 1 FILED
Jul 1, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Jul 1, 2022 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
May 19, 2022 ASGN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 4, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 9, 2021 NPUB
PUBLISHED FOR OPPOSITION
Nov 9, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 20, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 7, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 6, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 5, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 5, 2021 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 9, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 9, 2021 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 9, 2021 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 5, 2021 GNRN
NON-FINAL ACTION E-MAILED
Apr 5, 2021 GNRT
NON-FINAL ACTION WRITTEN
Apr 5, 2021 CNRT
ASSIGNED TO EXAMINER
Apr 2, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 8, 2021 NWOS
NEW APPLICATION ENTERED
Nov 13, 2020 NWAP